RAGE signaling regulates the progression of diabetic complications
Frontiers in Pharmacology · 16.03.2023 · 14
DOI: 10.3389/fphar.2023.1128872 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.03.2023. Verfasst von Kensei Taguchi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology, Kurume University School of Medicine, Kurume, Fukuoka, Japan. Die Arbeit wurde bisher 146-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Diabetes, the ninth leading cause of death globally, is expected to affect 642 million people by 2040. With the advancement of an aging society, the number of patients with diabetes having multiple underlying diseases, such as hypertension, obesity, and chronic inflammation, is increasing. Thus, the concept of diabetic kidney disease (DKD) has been accepted worldwide, and comprehensive treatment of patients with diabetes is required. Receptor for advanced glycation endproducts (RAGE), a multiligand receptor, belonging to the immunoglobulin superfamily is extensively expressed throughout the body. Various types of ligands, including advanced glycation endproducts (AGEs), high mobility group box 1, S100/calgranulins, and nucleic acids, bind to RAGE, and then induces signal transduction to amplify the inflammatory response and promote migration, invasion, and proliferation of cells. Furthermore, the expression level of RAGE is upregulated in patients with diabetes, hypertension, obesity, and chronic inflammation, suggesting that activation of RAGE is a common denominator in the context of DKD. Considering that ligand–and RAGE–targeting compounds have been developed, RAGE and its ligands can be potent therapeutic targets for inhibiting the progression of DKD and its complications. Here, we aimed to review recent literature on various signaling pathways mediated by RAGE in the pathogenesis of diabetic complications. Our findings highlight the possibility of using RAGE–or ligand–targeted therapy for treating DKD and its complications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Nephrology, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Zitieren
APA
Taguchi, K., & Fukami, K. (2023). RAGE signaling regulates the progression of diabetic complications. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1128872
Vancouver
Taguchi K, Fukami K. RAGE signaling regulates the progression of diabetic complications. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1128872
BibTeX
@article{Taguchi2023,
author = {Taguchi, Kensei and Fukami, Kei},
title = {RAGE signaling regulates the progression of diabetic complications},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1128872}
}
EUVIMED